Background: Potential therapeutic benefits of natural phytoconstituents and the emergence of nano-structured drug delivery systems have expanded the scope of enhanced chemotherapy with minimal adverse effects. Various in vivo and in vitro studies have revealed Resveratrol to be a potent anti-carcinogenic agent. Researchers are currently applying the concept of nano-science for enhancing the delivery of phyto-drugs like resveratrol, in order to carry the drug to the affected tissues and organs of cancer patients with much ease and efficiency.
Methods: The current review emphasizes the use of inorganic nanoparticles for enhancing the delivery and efficacy of resveratrol into otherwise inaccessible tumorigenic tissues.
Conclusion: The present review work summarizes a comprehensive update on the mechanism of actions of the resveratrol-based inorganic nanocomposite particles that are currently being studied against various cancer models. This work may be significant in laying the foundation for the future of metallic nanoparticles-based delivery and efficacy of phytochemicals in general and resveratrol in specific against non-invasive metastatic cancer. Read now:https://bit.ly/3QwJtS4
Coordinative interactions between multivalent metal ions and drug derivatives with Lewis base functions give rise to nanoscale coordination polymers (NCPs) as delivery systems. As the pharmacologically active agent constitutes a main building block of the nanomaterial, the resulting drug loadings are typically very high. By additionally selecting metal ions with favorable pharmacological or physicochemical properties, the obtained NCPs are predominantly composed of active components which serve individual purposes, such as pharmacotherapy, photosensitization, multimodal imaging, chemodynamic therapy or radiosensitization. By this approach, the assembly of drug molecules into NCPs modulates pharmacokinetics, combines pharmacological drug action with specific characteristics of metal components and provides a strategy to generate tailorable multifunctional nanoparticles. This article reviews different applications and recent examples of such highly functional nanopharmaceuticals with a high ‘material economy’.
Lay Summary: Nanoparticles, that are small enough to circulate in the bloodstream and can carry cargo molecules, such as drugs, imaging or contrast agents, are attractive materials for pharmaceutical applications. A high loading capacity is a generally aspired parameter of nanopharmaceuticals to minimize patient exposure to unnecessary nanomaterial. Pharmaceutical agents containing Lewis base functions in their molecular structure can directly be assembled into metal-organic nanopharmaceuticals by coordinative interaction with metal ions. Such coordination polymers generally feature extraordinarily high loading capacities and the flexibility to encapsulate different agents for a simultaneous delivery in combination therapy or ‘theranostic’ applications. Read now:https://bit.ly/3PcOi1F
Background: The application of nanotechnology has been considered a powerful platform in improving the current situation in drug delivery and cancer therapy, especially in targeting the desired site of action.
Objective: The main objective of the patent review is to survey and review patents from the past ten years that are related to the two particular areas of nanomedicines.
Methods: The patents related to the nanoparticle-based inventions utilized in drug delivery and cancer treatment from 2010 onwards were browsed in databases like USPTO, WIPO, Google Patents, and Free Patents Online. After conducting numerous screening processes, a total of 40 patents were included in the patent analysis. See the PRISMA checklist 2020 checklist.
Results: Amongst the selected patents, an overview of various types of nanoparticles is presented in this paper, including polymeric, metallic, silica, lipid-based nanoparticles, quantum dots, carbon nanotubes, and albumin-based nanomedicines.
Conclusion: Nanomedicines’ advantages include improvements in terms of drug delivery, bioavailability, solubility, penetration, and stability of drugs. It is concluded that the utilization of nanoparticles in medicines is essential in the pursuit of better clinical practice. Read now:https://bit.ly/3zDFTjd
Recent Advances in Drug Delivery and Formulation publishes editorials, mini-reviews, full-length research and review articles, and short technical notes from academia, industry, and regulatory agencies worldwide. The journal’s scope covers topics related to preformulation, formulation development, manufacturing technologies, biopharmaceutics, and regulatory science of both small molecules and biomolecules. These areas include, but are not limited to pharmaceutical nanotechnology, quality by design and process analytical technology, biosimilars and biowaivers, simulation modeling. The journal also publishes guest-edited thematic issues by eminent scientists on current topics that are timely and relevant for both industry and academia. Journal’s ambition is to serve as a means for the dissemination of current fundamental and innovative science including regulatory aspects and stimulate the development of innovative technologies and products for various applications in pharmaceutical sciences and biotechnology. Read more:https://bit.ly/3vlp2iK
The seventh volume of the series covers topics such as drug delivery, new avenues for treatment of esophageal cancer and the role of nutrigenomics in finding new therapies.
Topics in Anti-Cancer Research covers important advances on both experimental (preclinical) and clinical cancer research in drug development. The book series offers readers an insight into current and future therapeutic approaches for the prevention of different types of cancers, synthesizing new anti-cancer agents, new patented compounds, targets and agents for cancer therapy as well as recent molecular and gene therapy research.
The comprehensive range of themes covered in each volume will be beneficial to clinicians, immunologists, and R&D experts looking for new anti-cancer targets and patents for the treatment of neoplasms, as well as varied approaches for cancer therapy.
The latest volume of the series starts with a review on non-coding RNAs and associated patents. These patents help researchers to identify various cancer biomarkers and oncogenic regulatory mechanisms. 3 chapters cover nanocarrier patents for enhanced drug delivery of chemotherapeutic agents. Nanocarriers allow drug manufacturers to encapsulate chemotherapeutic agents within thin membranes which allows the molecules to reach the targeted cellular location in the body. The specific topics refer to Nanotaxol which is a nanotechnology enhanced version of Taxol® – a chemotherapeutic agent derived from chemicals in the bark of Taxus brevifolia, stimuli responsive nanocarriers which change behavior according to temperature and pH and smart nanoformulations which rely on different chemical formulations to reach molecular targets. Other topics covered in this volume include the role of autophagy in esophageal cancer, and nutrigenomics (the science of how biological nutrients affect gene expression) in cancer research. In terms of patents, the reader will find a list of compounds which modulate autophagy, and nutrigenomic methods that allow researchers to understand nutritional biomarkers of disease and customize nutraceutical formulations based on genetic and metabolic factors, respectively. To read out more, please visit:https://ebooks.benthamscience.com/book-highlights/190102001/
Drug Delivery Letters published by Bentham Science Publishers, has been accepted for inclusion in Scopus. Scopus is the largest abstract and citation database of peer-reviewed literature including scientific journals, books and conference proceedings.
Drug Delivery Letters publishes letters, original research papers, mini and full length reviews and guest edited issues in all important aspects of drug delivery, gene delivery, and drug targeting.The journals’ scope covers all the basic and applied research in drug delivery and targeting at molecular and cellular levels and novel delivery systems. The journal also focuses on all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines and gene delivery, etc. The manuscript submission process is fully electronic to ensure rapid publication of research results.
Author(s): Rafael Martín-Rapun, Laura De Matteis, Alfredo Ambrosone, Sonia Garcia-Embid, Lucia Gutierrez, Jesus M. de la Fuente
Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive.
Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed.
Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration.
Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies.
This article by Kendrick B. Turner and Scott A. Walper is published in Drug Delivery Letters, Volume 7, Issue 2, 2017
Outer membrane vesicles, biological nanoparticles shed during normal growth by bacteria, have seen significant recent advances in engineering and are thus finding new utility as therapeutic and drug delivery agents. One specific research focus explored recently in the literature is the use of bacterial vesicles as adjuvants in vaccine formulations. Early success in this area has demonstrated protection against infection by a number of bacterial species in animal models by engineering vesicles to display species-specific antigens as cargo, either within the interior of the vesicles or displayed on the exterior vesicle surface. In an effort to highlight recent advances in this field, this article explores recent and ongoing efforts to develop novel engineering methods aimed at providing new functionalities for bacterial vesicles as they apply to vaccine formulations. Specifically emerging technologies for engineering these structures, including cargo loading and surface modification will be explored. Bacterial vesicles show great promise as biologically-, derived nanoparticles that could function as a platform technology in a variety of fields. With continued development of novel engineering tools, and an increased understanding in their biogenesis and biological fate in living systems there is significant potential to develop bacterial vesicles as tools for not only vaccine development but also for use in the delivery of therapeutic compounds to targeted cells.
You must be logged in to post a comment.